利奈唑胺治疗危重患者革兰阳性球菌的疗效和安全性

The Efficacy and Safety of Linezolid in Treatment of Patients with the Gram-positive Cocci Infections in ICU

目的:通过应用利奈唑胺治疗革兰阳性球菌感染的危重患者,了解其疗效和安全性。方法:收集和分析2009年1月—2010年3月用利奈唑胺治疗革兰阳性球菌感染26例危重患者的临床资料。结果:利奈唑胺治疗总有效率为73.07%,细菌清除率为81.4%,不良反应发生率为15.38%,未见严重不良反应。结论:利奈唑胺治疗重症患者的革兰阳性球菌感染的疗效确切,不良反应较少。

Objective：Through the treatment of patients with the gram-positive Cocci infections with the Linezolid,to evaluated the efficacy and safety of Linezolid.Methods：Retrospective analysis of 26 patients who treated with Linezolid,suffered form gram-positive Cocci infections,including clinical efficacy and adverse reaction.Results： The total efficacy rate was 73.07%,and adverse reaction rate was 15.38%,no serious reaction.Conclusions： Linezolid could provide conspicuous effectiveness and satisfactory bacterium clearance rate in treatment of gram-positive cocci infection in ICU,cause less adverse reaction.